Further and based on the results of the CACOV registry, the randomized “C-reactive protein Apheresis for Attenuation of Pulmonary, Myocardial and/or Kidney Injury in COVID-19” (CAPMYKCO; NCT04898062) trial was designed. This evidence concerns the gene CRP and COVID-19.